Rituximab increases peripheral natural killer cells in patients with rheumatoid arthritis

The clinical response of rituximab (RTX) is related to the degree of B cell depletion, although other circulating lymphocytes may be affected. We investigated the changes in lymphocyte sub-populations in rheumatoid arthritis (RA) patients treated with RTX and their relationship with the therapeutic...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2017-03, Vol.35 (2), p.241-246
Main Authors: Giollo, Alessandro, Viapiana, Ombretta, Carletto, Antonio, Ortolani, Riccardo, Biasi, Domenico, Gatti, Davide, Adami, Silvano, Rossini, Maurizio
Format: Article
Language:English
Subjects:
Adult
Aged
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - immunology
Biomarkers - blood
CD56 Antigen - blood
Female
Flow Cytometry
GPI-Linked Proteins - blood
Humans
Immunophenotyping - methods
Killer Cells, Natural - drug effects
Killer Cells, Natural - immunology
Lymphocyte Count
Male
Middle Aged
Phenotype
Receptors, IgG - blood
Rituximab - adverse effects
Rituximab - therapeutic use
Severity of Illness Index
Time Factors
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical response of rituximab (RTX) is related to the degree of B cell depletion, although other circulating lymphocytes may be affected. We investigated the changes in lymphocyte sub-populations in rheumatoid arthritis (RA) patients treated with RTX and their relationship with the therapeutic response, with attention to natural killer (NK) cells. In fifty-one RA patients peripheral blood B and T lymphocytes and NK cells subtypes were counted by flow cytometry before and 3, 6 and 12 months after RTX administration. Patients were evaluated for disease activity with DAS28-CRP and EULAR response criteria at each visit. RTX significantly increased from baseline values CD56+3- cells (28 %, 19 % and 25 %; p
ISSN:0392-856X